November 12th 2024
A 12-week regimen showed significant reductions in wrinkle severity and pigment improvement.
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis
November 21, 2024 - December 5, 2024
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Meet the Aesthetic Expert with Dr Will Kirby: Todd Tillemans, Cynosure CEO
August 30th 2021In this month’s “Meet the Aesthetic Expert” column, Will Kirby, DO, FAOCD, talks with Todd Tillemans, chief executive officer of Cynosure, about his journey from Marine to the aesthetics industry, investing in technology, and improving patient accessibility.
Rare Cryolipolysis Complications
August 24th 2021When used incorrectly or inaccurately, cryolipolysis can, in rare cases, result in SAEs including dysesthesia, pain, paradoxical adipose hyperplasia, skin blanching, vasovagal reactions, skin hyperpigmentation, contour irregularities, and nerve injuries.
FDA Clears ellacor Micro-Coring Technology for Wrinkles
August 11th 2021Roy Geronemus, MD, clinical professor of dermatology at New York University Medical Center & Dermatology Times editorial advisory board member, discusses the recent FDA clearance of ellacor Micro-Coring Technology for treatment of moderate to severe wrinkles in the mid to lower face.